Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A comparison of the lowest effective concentration in culture media for detection of chromosomal damage in vitro and in blood or plasma for detection of micronuclei in vivo.

Autor: Kirkland D; Kirkland Consulting, PO Box 79, Tadcaster LS24 0AS, UK. Electronic address: dkirkland@genetoxconsulting.co.uk., Whitwell J; Labcorp Drug Development, Otley Road, Harrogate HG3 1PY, UK., Smith R; Labcorp Drug Development, Otley Road, Harrogate HG3 1PY, UK., Hashimoto K; Takeda Pharmaceutical Company Limited, Research, Drug Safety Research and Evaluation, Fujisawa, Japan., Ji Z; Bristol Myers Squibb Company, Nonclinical Safety, 1 Squibb Drive, New Brunswick, NJ 08903, USA., Kenny J; GlaxoSmithKline, Park Road, Ware SG12 0DP, UK., Koyama N; Eisai Co., Ltd, Global Drug Safety, Tsukuba-shi, Ibaraki, Japan., Lovell DP; Public Health Research Institute (PHRI), St George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, UK., Martus HJ; Novartis Institutes for BioMedical Research, Preclinical Safety, 4002 Basel, Switzerland., Meurer K; BASF SE, Li444, Speyererstrasse 2, 67117 Limburgerhof, Germany., Roberts D; Charles River Laboratories, Skokie, IL, USA., Takeiri A; Chugai Pharmaceutical Co., Ltd., Translational Research Div., 1-135 Komakado, Gotemba, Shizuoka, Japan., Uno Y; LSI Medience Co., 1-13-4, Tokyo 101-8517, Japan., van der Leede BJ; Non-Clinical Safety, Janssen Research & Development, a Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, 2340 Beerse, Belgium., White P; Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada., Zeller A; F. Hoffmann-La Roche Ltd., Pharmaceutical Sciences, pRED Innovation Center Basel, 4070 Basel, Switzerland.

Publikováno v: Mutation research. Genetic toxicology and environmental mutagenesis [Mutat Res Genet Toxicol Environ Mutagen] 2022 Jul-Aug; Vol. 879-880, pp. 503503. Date of Electronic Publication: 2022 May 28.

Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.

Autor: Lachau-Durand S; Drug Metabolism and Pharmacokinetics, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Lammens L; Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., van der Leede BJ; Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Van Gompel J; Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Bailey G; Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Engelen M; Project Management Office, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium., Lampo A; Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

Publikováno v: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2019 Jan 16; Vol. 13 (1), pp. e0007026. Date of Electronic Publication: 2019 Jan 16 (Print Publication: 2019).

Performance and data interpretation of the in vivo comet assay in pharmaceutical industry: EFPIA survey results.

Autor: van der Leede BJ; Janssen Research & Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium. Electronic address: bvdleede@its.jnj.com., Doherty A; AstraZeneca, Drug Safety and Metabolism, Cambridge, United Kingdom., Guérard M; F. Hoffmann-La Roche, Pharmaceutical Science, Pharma Research and Early Development (pRed), Basel, Switzerland., Howe J; GlaxoSmithKline R&D, Safety Assessment, Ware, United Kingdom., O'Donovan M; Consultant Genetic Toxicologist, Nottingham, United Kingdom., Plappert-Helbig U; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Thybaud V; Sanofi, Drug Disposition, Preclinical Safety and Animal Research, Vitry sur Seine, France.

Publikováno v: Mutation research. Genetic toxicology and environmental mutagenesis [Mutat Res Genet Toxicol Environ Mutagen] 2014 Dec; Vol. 775-776, pp. 81-8. Date of Electronic Publication: 2014 Oct 05.

International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories.

Autor: Dertinger SD; Litron Laboratories, Rochester, New York, USA. sdertinger@litronlabs.com, Phonethepswath S, Weller P, Nicolette J, Murray J, Sonders P, Vohr HW, Shi J, Krsmanovic L, Gleason C, Custer L, Henwood A, Sweder K, Stankowski LF Jr, Roberts DJ, Giddings A, Kenny J, Lynch AM, Defrain C, Nesslany F, van der Leede BJ, Van Doninck T, Schuermans A, Tanaka K, Hiwata Y, Tajima O, Wilde E, Elhajouji A, Gunther WC, Thiffeault CJ, Shutsky TJ, Fiedler RD, Kimoto T, Bhalli JA, Heflich RH, MacGregor JT

Publikováno v: Environmental and molecular mutagenesis [Environ Mol Mutagen] 2011 Dec; Vol. 52 (9), pp. 690-8. Date of Electronic Publication: 2011 Sep 11.